Pharvaris Revenue
Pharmaceutical Manufacturing • 
Zug, Zug, Switzerland • 101-200 Employees
Pharvaris revenue & valuation
| Annual revenue | $11,200,000 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues | $35,600,000 |
| Total funding | $501,200,000 |
Key Contacts at Pharvaris
Juan Bravo Vargas
Director Of Operational Excellence And Digital Innovation
Flore-Mélissa Lombard
Sr Director, Global Ra Cmc Lead
Michael Staroverov
Enterprise It Architect, Executive Director
Christoph Cirillo
Senior Director, Clinical Operations Program Lead
Salvador Domínguez
Associate Director, Program Management Clinical
Maggie Beller
Executive Director, Head Of Corporate And Investor Communications
Jaya Vatsyayan
Senior Director, Clinical Science | Clinical Development
Neda Rafiei
Senior Director Clinical Supplies Lead
Miranda Van Loon
Senior Payroll And Hr Administration Lead | Associate Director
Joachim Heizmann
Senior Director Cmc And Pharmaceutical Development
Company overview
| Headquarters | Grafenauweg 8, Zug, 6300, CH |
| Phone number | +4116469425631 |
| Website | |
| NAICS | 3254 |
| SIC | 283 |
| Keywords | Biotechnology, Pharmaceuticals, Drug Discovery, Drug Development, Medicinal Chemistry, Hereditary Angioedema |
| Founded | 2015 |
| Employees | 101-200 |
| Socials |
Pharvaris Email Formats
Pharvaris uses 4 email formats. The most common is {first initial}.{last name} (e.g., j.doe@pharvaris.com), used 57.9% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}.{last name} | j.doe@pharvaris.com | 57.9% |
{first name}.{last name} | john.doe@pharvaris.com | 37.9% |
{first initial}{last name}{last name}{first initial}.{last name} | jdoedoej.doe@pharvaris.com | 2.1% |
{first initial}.{second initial}{last name} | j.odoe@pharvaris.com | 2.1% |
About Pharvaris
Pharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of HAE and other bradykinin-mediated diseases. The company brings together executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE. The company reunites the core team responsible for the discovery and approval of the HAE treatment icatibant. With novel small molecules, we have identified and are advancing potent, orally available compounds targeting this clinically proven therapeutic target.
Employees by Management Level
Total employees: 101-200
Seniority
Employees
Employees by Department
Pharvaris has 55 employees across 12 departments.
Departments
Number of employees
Funding Data
Explore Pharvaris's funding history, including investment rounds, total capital raised, and key backers.
Pharvaris Tech Stack
Discover the technologies and tools that power Pharvaris's digital infrastructure, from frameworks to analytics platforms.
Performance
Maps
JavaScript libraries
CDN
Marketing automation
Font scripts
JavaScript libraries
Miscellaneous
Security
Programming languages
Blogs
United Kingdom
Bangladesh
Spain
New ZealandFrequently asked questions
4.8
40,000 users
